St Luke’s Hospital starts augmented stereotactic body radiotherapy using Raypilot

Treatment with augmented stereotactic body radiotherapy (ASBRT) and the Raypilot system has begun at St Luke’s Hospital in Dublin, Ireland. The first patient was treated with a team from manufacturer Micropos Medical present on site.

St Luke’s Hospital has entered into a rental agreement for the Raypilot system in order to evaluate the technology while integrating five-fraction SBRT into its daily clinical workflow. The objective is for ASBRT to become part of the standard treatment for prostate cancer at the clinic.

Lead radiation oncologist Dr Alex Boychak said: “With the Raypilot system, we can see exactly where we are delivering the radiation. Being able to deliver the dose in the right place at the right time gives us confidence in the treatment. Above all, this allows our patients to benefit from a safe, modern and efficient treatment method with a reduced risk of side effects.”

Micropos Medical is working to raise awareness of modern radiotherapy as a relevant treatment option for prostate cancer, offering advantages for both patients and healthcare providers. CEO Richard Forsberg said: “There is now substantial evidence that modern radiotherapy is a safe and effective prostate cancer treatment, providing significant benefits for patients. We want to increase knowledge and awareness of this. For us, the start at St Luke’s Hospital represents an important milestone, and we are pleased to see ASBRT begin to be adopted as a standard treatment.”

Picture: consultant radiation oncologist Dr Alex Boychak, clinical specialist radiation therapist Hazel Fitzpatrick, physicist Evan Wolfe, principal physicist Dr Elaine Tyner and Micropos Medical installation specialist Dr Jonathan Tranel.

Published on the front page of the March 2026 issue of RAD Magazine.